Skip to Main Content

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer

Conditions

Breast

What is the purpose of this trial?

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.

  • Trial with
    Southwest Oncology Group (SWOG)
  • Start Date
    11/29/2018
  • End Date
    12/31/2021
Trial Image

For more information about this study, contact:

Trisha Burrello

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/11/2020
  • Study HIC
    #2000024170